瘀血痹片通过抑制LOX/Ras/Raf-1信号发挥抗血管生成作用治疗实验性类风湿关节炎
该研究评价瘀血痹片(YXB)在胶原诱导性关节炎(CIA)大鼠和VEGF诱导的HUVEC中的抗血管生成活性及机制。YXB减轻CIA大鼠疾病严重程度和骨破坏,抑制滑膜血管生成及CD31、VEGF表达。机制上YXB剂量依赖性抑制LOX/Ras/Raf-1信号,效果优于甲氨蝶呤。
要点
- YXB可减轻CIA大鼠关节炎严重程度和骨破坏。
- YXB抑制滑膜血管生成及CD31、VEGF表达。
- YXB通过抑制LOX/Ras/Raf-1信号发挥抗血管生成作用。
核心结论
- YXB可能通过抑制LOX/Ras/Raf-1信号抑制血管生成,从而减轻RA疾病严重程度和骨侵蚀。
研究设计与样本
- 研究采用CIA大鼠模型和VEGF诱导的HUVEC,结合转录调控网络分析和网络药理学探讨机制。
- 体内通过关节炎发生率、评分和micro-CT评价抗关节炎效果,通过组织学和免疫组化评价抗血管生成效果。
- 体外通过划痕愈合、Transwell迁移、Transwell侵袭和管形成实验评价抗血管生成效果。
- 采用Western-blotting和免疫组化分析分子机制。
主要发现
- YXB减轻CIA大鼠疾病严重程度并改善病理特征。
- YXB显著减少骨破坏和滑膜血管生成。
- YXB有效抑制血管生成标志物CD31和VEGF表达。
- 体外YXB有效抑制HUVEC迁移、侵袭和管形成。
- YXB剂量依赖性降低CIA大鼠LOX、Ras、Raf-1表达及MEK和ERK磷酸化,效果优于甲氨蝶呤。
临床怎么用
- YXB作为中药复方制剂,在CIA大鼠中显示抗血管生成和减轻骨破坏的作用,机制涉及LOX/Ras/Raf-1信号抑制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: A Chinese patent medicine derived from a classical traditional Chinese medicine formula, Yu-Xue-Bi tablet (YXB) is widely used in the clinic to treat rheumatoid arthritis (RA). During the progression of RA, angiogenesis plays a central role in fostering the production of inflammatory cells, leading to synovial hyperplasia and bone destruction. However, whether YXB attenuates the angiogenesis during RA progression remains to be defined. AIM OF THE STUDY: We aimed to evaluate the anti-angiogenic activity of YXB and explore its mechanism of action in collagen-induced arthritis (CIA) rats and VEGF-induced HUVECs. MATERIALS AND METHODS: Transcriptional regulatory network analysis and a network pharmacology approach were employed to explore mechanism of YXB in RA angiogenesis. The antiarthritic effect of YXB was evaluated by determining the arthritis incidence, and score, and by micro-CT analysis. The anti-angiogenic effect of YXB in vivo was assessed by histological and immunohistochemical analyses. The anti-angiogenic effect of YXB in vitro was assessed by wound healing, Transwell migration, Transwell invasion, and tube formation assays. Western-blotting and immunohistochemical analysis were employed to explore the molecular mechanisms of YXB. RESULTS: YXB reduced disease severity and ameliorated pathological features in CIA rats. YXB markedly decreased bone destruction and synovial angiogenesis. Consistently, we also demonstrated that YXB effectively suppressed angiogenesis marker CD31 and VEGF expression. In vitro, YXB effectively inhibited HUVEC migration, invasion, and tube formation. Following the identification of transcriptional expression profiles, "YXB putative targets-known RA-related genes-genes associated with the therapeutic effect of YXB" interaction network was constructed and analyzed. After that, the LOX/Ras/Raf-1 signaling axis, which is involved in RA angiogenesis, was identified as one of the candidate mechanisms of YXB against RA. Experimentally, YXB dose-dependently decreased the expression levels of LOX, Ras, and Raf-1, as well as the phosphorylation of MEK and ERK in CIA rats, and these effects were better than the inhibitory effects of methotrexate (MTX), an FDA approved drug used for some autoimmune diseases such as RA. In addition, YXB may function as a potent angiogenesis inhibitor and significantly suppress the VEGF-induced activation of LOX/Ras/Raf-1 signaling in vitro. CONCLUSIONS: We provide evidence that YXB may decrease the disease severity of RA and reduce bone erosion by suppressing angiogenesis via inhibition of LOX/Ras/Raf-1 signaling.
引用
- Su X, Yuan B, Tao X, et al. Anti-angiogenic effect of YuXueBi tablet in experimental rheumatoid arthritis by suppressing LOX/Ras/Raf-1 signaling. J Ethnopharmacol. 2022. PMID: 35952969. doi:10.1016/j.jep.2022.115611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。